Manabu Fujita, MD
About
Cancer has been a deeply personal part of my life and career. My father and brother were both surgical oncologists, and I lost my mother to cancer at a young age. These experiences have shaped the way I care for patients—not only as a surgeon, but also as someone who understands how profoundly a cancer diagnosis can affect patients and their families.
My goal is to provide comprehensive, individualized cancer care using the most advanced surgical techniques available. I specialize in complex surgical oncology, including minimally invasive and robotic surgery for gastrointestinal, pancreatic, liver, colorectal, and other cancers. Throughout my career, I have performed and supervised a high volume of complex oncologic procedures while also training residents and future surgeons.
I strongly believe that no patient should have to carry the physical, emotional, and psychological burden of cancer alone. Cancer treatment requires teamwork, and that team extends far beyond the physicians directly involved in treatment. It includes surgeons, medical oncologists, radiation oncologists, gastroenterologists, radiologists, pathologists, nurses, and other healthcare professionals, but it also includes the patient's family, friends, and local community support organizations. Each of these individuals can play an important role in helping patients navigate the challenges of diagnosis, treatment, recovery, and survivorship.
For me, cancer care is therefore not limited to performing an operation or treating a tumor. It is about surrounding the patient with a network of support, sharing the challenges that arise during treatment, and helping patients and their families move through those challenges together. I believe that close communication among the medical team, the patient, the patient's loved ones, and available community resources can make a meaningful difference in the overall cancer experience.
As a surgeon and a surgical oncologist, I aim for cure through complete cancer removal whenever possible. At the same time, I recognize that cancer is a systemic and biologically complex disease, and even after successful surgery there may be a risk of microscopic or distant disease. For that reason, I believe strongly in multidisciplinary care and close collaboration with medical oncology, radiation oncology, and clinical research teams to develop the most appropriate treatment strategy for each individual patient.
Research and innovation are also important parts of my practice. My background includes cancer genetics, targeted drug-delivery research, translational oncology, and more recently, the evaluation of artificial intelligence in cancer care and clinical decision-making. I am particularly interested in how emerging technologies and clinical research can improve treatment options for patients with complex or advanced cancers.
Above all, I consider it a privilege to care for patients and their families during one of the most difficult periods of their lives. My goal is to provide not only advanced and thoughtful surgical cancer care, but also compassionate guidance and a sense of partnership so that patients know they are not facing cancer alone.
Languages
Education
Medical Board Certifications
Fellowship
Residencies
Internship
Degrees
Recognitions
- 2004 AACR Avon Foundation Scholar-in-Training Award
- 2007 AACR-Aflac, Inc. Award
- 2012 Outstanding Student Teaching Awards (Cedars-Sinai Medical Center)
- See More
Locations
Westlake Village Cancer Care
Medical Services
Areas of Focus
Research
Publications
- Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T, Yamaoka Y, Nakamura Y. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nature Genetics, 24: 245-250, 2000.
- Fujita M, Furukawa Y, Tsunoda T, Tanaka T, Ogawa M, Nakamura Y. Up-regulation of the ENC1 (ectodermal-neural cortex 1) gene, a downstream target of the beta-catenin/Tcf complex, in colorectal carcinomas. Cancer Research, 61: 7722-7726, 2001.
- Fujita M, Khazenzon NM, Bose S, Sekiguchi K, Sasaki T, Carter WG, Ljubimov AV, Black KL and Ljubimova JY. Overexpression of b1 chain-containing laminins in capillary basement membranes of human breast cancer and its metastases. Breast Cancer Research, 7: R411-421, 2005.
- Kirchoff DD, Deutsch GB, Fujita M, Lee DY, Sim MS, Lee JH, Bilchik AJ. Overall Survival Is Impacted by Birthplace and Not Extent of Surgery in Asian Americans with Resectable Gastric Cancer. J Gastrointest Surg. 2015 Nov;19(11):1966-73. doi: 10.1007/s11605-015-2919-8. Epub 2015 Aug 26.
- Uppal A, Stern S, Thompson JF, Foshag L, Mizzollo N, Nieweg OE, Hoekstra HJ, Roses DF, Sondak VK, Kashani-Sabet M, Coventry BJ, Cochran AJ, Fujita M, Sim-Shin M, Elashoff D, Elashoff RM, Faries MB. Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease. Ann Surg Oncol. 2020 Jun;27(6):1970-1977. doi: 10.1245/s10434-019-08086-0. Epub 2019 Dec 20.
- Pandya S, Bresler TE, Wilson T, Htway Z, Fujita M. Decoding the NCCN Guidelines With AI: A Comparative Evaluation of ChatGPT-4.0 and Llama 2 in the Management of Thyroid Carcinoma. Am Surg. 2025 Jan;91(1):94-98. doi: 10.1177/00031348241269430. Epub 2024 Aug 13.
- Bresler TE, Wilson T, Makaryan T, Pandya S, Palmer K, Meyer R, Htway ZM, Fujita M. AI at the Forefront: Navigating Oncologic Care for Six Gastrointestinal Cancers According to the NCCN Guidelines Utilizing Gemini-1.0 Ultra and ChatGPT-4. J Surg Oncol. 2025 Aug;132(2):317-322. doi: 10.1002/jso.70005. Epub 2025 Jun 19. PMID: 40536141
- Pandya S, Wilson T, Meyer R, Bresler TE, Fujita M. Artificial Intelligence in Surgical Education: A Pilot Study Using ASCRS Guideline-Derived Questions. Am Surg. 2026 Apr 19:31348261443342. doi: 10.1177/00031348261443342. Online ahead of print. PMID: 42003211
- Meyer R, Bresler TE, Palmer KM, Wilson T, Pandya S, Fujita M. Evaluating the Accuracy of ChatGPT-4o in Addressing Complex Clinical Questions Based on NCCN Guidelines for Rectal Adenocarcinoma. J Surg Oncol. 2026 Jul 5. doi: 10.1002/jso.70314. Online ahead of print. PMID: 42402154
- Meyer RJ, Bresler TE, Makaryan TT, Gheissari R, Mauch A, Fujita M. Correct but Incomplete: Limitations of AI-Assisted Decision Support in Rectal Cancer. Am Surg. 2026 Jul 24:31348261471501. doi: 10.1177/00031348261471501. Online ahead of print. PMID: 42498996
Insurance
- Aetna
- Anthem Blue Cross
- Blue Shield of California
- Centivo
- Cigna
- First Health
- Health Net of California
- Interplan (part of HealthSmart)
- Medicare Advantage
- MultiPlan
- UFCM Health System
- Prime Health Services
- Private Healthcare Systems (PHCS)
- TRICARE
- UnitedHealthcare
The list of healthcare plans above may not be comprehensive and could change.
Please contact your benefits coordinator or health insurance company directly to verify coverage.
Visit our health insurance information page for more details.
Recognitions
- 2004 AACR Avon Foundation Scholar-in-Training Award
- 2007 AACR-Aflac, Inc. Award
- 2012 Outstanding Student Teaching Awards (Cedars-Sinai Medical Center)
- 2013 William Randolph Hearst Foundations Fellow (John Wayne Cancer Institute
- 2023 Champion of the Quarter / Physician (Los Robles Medical Center)